chrisvoncsefalvay/vaers-outcomes huggingface dataset:
diarrhoea (last night); fatigue; left arm became swollen; left arm became red; left arm reacted more; Achiness; loss of appetite; upset stomach; "freezing to death"; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (left arm reacted more), PAIN (Achiness), DECREASED APPETITE (loss of appetite), ABDOMINAL DISCOMFORT (upset stomach) and FEELING COLD ("freezing to death") in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012F21A, 002A21A and 013L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (Allergic to tramadol).   On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Nov-2021, the patient experienced VACCINATION SITE REACTION (left arm reacted more), PAIN (Achiness), DECREASED APPETITE (loss of appetite), ABDOMINAL DISCOMFORT (upset stomach), FEELING COLD ("freezing to death"), FATIGUE (fatigue), VACCINATION SITE SWELLING (left arm became swollen) and VACCINATION SITE ERYTHEMA (left arm became red). On 07-Nov-2021, the patient experienced DIARRHOEA (diarrhoea (last night)). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Adverse event, at a dose of 1 dosage form and IBUPROFEN for Adverse event, at a dose of 1 dosage form. At the time of the report, VACCINATION SITE REACTION (left arm reacted more), PAIN (Achiness), DECREASED APPETITE (loss of appetite), ABDOMINAL DISCOMFORT (upset stomach), FEELING COLD ("freezing to death"), DIARRHOEA (diarrhoea (last night)), VACCINATION SITE SWELLING (left arm became swollen) and VACCINATION SITE ERYTHEMA (left arm became red) was resolving and FATIGUE (fatigue) had not resolved.            Concomitant medications were not reported. The caller reported his wife is feeling better on 08 Nov 2021
Janssen vaccine given as 2nd dose of Pfizer vaccine in error.  {patient was immediately advised of same, and reassured that he would be fully vaccinated .  side effects were discussed and all questions were answered.  He will be contacted for follow up in several days and advised to call the Health Dept or his PCP if any concerns.
the first couple of days were fine, 1 week later Itwas a nasty rash a few inches around my arm, raised, hot, red, it looked like an infection and I went to the Dr they prescribed antibiotics, two days into medication it went away, the spot itches every now and then but it's not a rash anymore
pt presented to ED with c/o SOB x 3 days; fever, headache, fatigue, nausea, left sided chest pain; positive for COVID; DNR/DNI; pt went into respiratory arrest in ED, BiPAP attempted but was unsuccessful; pt died in the ED
Narrative:  75 YOM received Moderna COVID vaccines on 1/19/21 and 2/16/21. Patient admitted to hospital and tests positive for COVID-19 on 10-25-21. Patient later died.
Rt arm is red and swollen in a 3 × 3 area and hot to touch. This are is in front of site of shot. Received shot on 2/22/2021 and noticed reaction 2/23/2021 after second vaccine.  Not sure to touch. Pain to lift arm first 24 hrs.
no adverse event; Nurse called to report VAXNEUVANCE that expired 9/30/2023 was administered today, 10/5/2023. Operator of device is an HCP/ Outbound call placed to Customer. Confirmed it was PNEUMOVAX23 not VAXNEUVANCE that was administered.; This spontaneous report was received from a nurse and refers to a 77-year-old patient with unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 05-OCT-2023, the patient received pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) injection, lot #W019533, has been verified to be a valid lot number, expiration date was reported as 30-SEP-2023, administered for prophylaxis (strength, and route of administration were not provided) (Expired vaccine used). No side effects or symptoms reported, no temperature excursion history. No additional AE/no PQC.
Hives and itching at injection site and elsewhere on body. Diphenhydramine oral administered for 1 week since. Symptoms persist, mildly, 1 week later.
Got shingles 2 weeks after covid vaccine; This is a spontaneous report from a contactable consumer (patient herself) via COVID-19 Adverse Event Self-Reporting Solution. A 46 years old non -pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: 6198) via an unspecified route, administered in Left Arm on 22Feb2021 at 14:15 (46-year-old at vaccination) as a Dose number unknown, Single for COVID-19 immunization. The patient was non-pregnant at time of vaccination. The patient medical history was not reported. No known allergies was reported. The patient's concomitant medication(s) included semaglutide (OZEMPIC), bupropion hydrochloride (WELLBUTRIN) within two weeks of vaccination. Vaccination Facility type was reported as Other. The patient was not diagnosed with Covid prior vaccination. The patient had not received any other vaccine in four weeks prior vaccination. On 03Mar2021 (2 weeks after covid vaccine), the patient had experienced shingles. These adverse event resulted in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care visit. The patient received Lyrica, acyclovir as treatment medication for the event. The patient had not tested for Covid post vaccination. The outcome of the event shingles was recovering.  No follow-up attempts are required. No further information is expected.
Patient presented to Medical Center on 01/11/2022 with c/o low oxygen.  Patient recently had tested positive for Covid-19.  In the ED the patient was 67% on RA and placed on 15L NRB.  Patient also c/o sore throat, malaise.  Chest xray consistent with Covid-PNA.  Patient was admitted and started on steroids.  Patient was administered remdesivir, and lovenox for DVT prophylaxis.  During the hospitalization he was noted to have ST elevation, and was taken to the Cath lab.  Patient received a stent to LAD, and was also found to have chronically occluded RCA.  He was placed on aspirin and prasugrel in addition to beta-blocker and ACE inhibitors.  Patient had worsening hypoxemia and was placed on CPAP, did not tolerate and was transferred to CCU.  Patient required intubation.  Patient required worsening shock refractory to high-dose vasopressor and expired on 01/29/2022.
fever; body aches; joint pain; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), MYALGIA (body aches) and ARTHRALGIA (joint pain) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014C21A and 036B21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: FLU VACCINE VII in September 2021. Past adverse reactions to the above products included No adverse event with FLU VACCINE VII. Concurrent medical conditions included Drug allergy (Erythromycin) and Drug allergy (Z-Pack).   On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 02-May-2021, the patient experienced PYREXIA (fever), MYALGIA (body aches) and ARTHRALGIA (joint pain). At the time of the report, PYREXIA (fever), MYALGIA (body aches) and ARTHRALGIA (joint pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was reported. No concomitant medication was reported.   This case was linked to MOD-2022-498916 (Patient Link).
Soreness in the arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness in the arm) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced PAIN IN EXTREMITY (Soreness in the arm). At the time of the report, PAIN IN EXTREMITY (Soreness in the arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported by the reporter. No treatment medications were provided by the reporter.   This case was linked to MOD-2021-085787 (Patient Link).
See attachment for complete history and observations - patient apparently suffered fatal interaction when Covid Vaccine interacted with active Multiple Sclerosis relapse.  Relapsing-Remitting MS case converted to aggressive Progressive MS, which,over the course of 1 year following the vaccine doses, rapidly accelarated the progression of lesions that cut off central nervous system commumication with legs, then arms, and, finally even lungs.  (I attempted to paste the complete report on this form, but it would not accept that kind of input, and the details require more than this page will accept.  Please contact me by email as indicated above if you are interested in the details.)
This case was received from a health professional on 25 September 2007, and is one in a cluster of three patients. The reporter is also the patient's father. A four-year-old female patient received an intramuscular deltoid injection of FLUZONE (lot number U2449AA) on 20 September 2007. Within 24 hours of vaccination, the patient developed an area of redness and soreness at the injection site, approximately two inches in diameter. The reporter diagnosed the event as cellulitis. The area was treated with antibiotic ointment, and the event resolved in "two to three days". Follow-up information received on 23-October 2007. Information concerning the patient's birth weight and number of siblings was reported. In response to a query asking if the patient had received a previous dose of FLUZONE and if there had been any reactions, it was reported that the patient had received five previous doses of FLUZONE. It was not reported whether or not the patient had any reactions to previous FLUZONE vaccinations. Date of FLUZONE vaccination, previously reported as 20 June 2007 in the structured field, has been corrected to 20 September 2007. The correct vaccination date was previously reported in the narrative field. A corrective version of the case was created using the previous receipt date for the sole purpose of correcting the FLUZONE lot number in the product screen.
Ringing in my ears, especially my left ear. I had no ringing after my first dose, only after my second.
Patient is experiencing Right Axilla Lymph Node swelling as well as headache and body aches.
Patient complained of redness on entire upper arm that is warm to touch. Redness has then traveled to around her elbow area.
+ "seizue" fever 101-103 F on 6-17-15 at about 9 am (24 hours after vaccination). DTAP, HIB, PREVNAR given 6-16-15.
This case was reported by a physician via call center representative and described the occurrence of therapeutic response decreased in a child male patient who received Hepatitis B vaccine. Co-suspect products included Hepatitis B vaccine, Hepatitis B vaccine, and Hepatitis B vaccine. On an unknown date, the patient received the 1st dose of Hepatitis B vaccine, the 2nd dose of Hepatitis B vaccine, the 3rd dose of Hepatitis B vaccine and the 2nd dose of Hepatitis B vaccine. On an unknown date, unknown after receiving Hepatitis B vaccine, Hepatitis B vaccine and Hepatitis B vaccine and not applicable after receiving Hepatitis B vaccine, the patient experienced therapeutic response decreased and incomplete course of vaccination. On an unknown date, the outcome of the therapeutic response decreased and incomplete course of vaccination were unknown. It was unknown if the reporter considered the therapeutic response decreased to be related to Hepatitis B vaccine, Hepatitis B vaccine and Hepatitis B vaccine. Additional information was reported as follows: The healthcare professional who was a physician was called on behalf of her son. The patient was previously vaccinated with Hepatitis B (unknown brand) with a 3 dose series as a baby and on an unknown date, the patient's hepatitis B titer was recorded as low. So the Healthcare professional was asking if they need to repeat the 3 dose series of Hepatitis B. After receiving 1st dose of Hepatitis B vaccine in July 2017, the patient did not receive 2nd dose of Hepatitis B vaccine which led to incomplete course of vaccination. The healthcare professional was asking if they need to restart the Hepatitis B series since it was longer than the recommended intervals. No further information was provided.
This spontaneous report was received from a registered nurse and refers to a 4 year old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 14-AUG-2017, the patient was vaccinated with an improperly stored dose of VARIVAX at a dose of 0.5 (units not specified) from lot # N012488 with expiry date: 20-APR-2019 (dose number, route, anatomical location and site of administration were not reported) for prophylaxis. Concomitant medications included a properly stored sterile diluent (manufacturer unknown). The administered dose of vaccine was stored in the temperature between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 20 hours and in the temperature between 15 degrees Fahrenheit and 46 degrees Fahrenheit for 6 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No additional information was provided. This is one of the several reports received from the same reporter. Sender's Comments: US-009507513-1707USA004945.
"having pain, swelling, redness in arm". Treatment included: antibiotics and steroids.
I received my first dose on March 24 in my left arm. My second dose on April 23 in my right arm. Developed a patch of bumps around the injection site on left arm on April 24, 2021. Went to the ER on April 25, around 9:00am. The doctor didn't know what it was and asked me put some antibiotic ointment on it. Monday, April 26, the bumps are larger and have spread to a different area on my arm. It was painful last night and still is painful today.
having elevated Heart Rate; shortness of breath; chest tightness; dizziness; interrupted sleep due to these symptoms; This is a spontaneous report from a contactable consumer, the patient herself. A 38-years-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot number: ER8727), via an unspecified route of administration, administered in Left arm on 26Mar2021 at 09:15 am as dose 1, single (at the age of 38 years), for covid-19 immunization. Medical history was reported as none. There were no allergies to medications, food, or other products. Concomitant medications were not reported. Other medications the patient received within 2 weeks of vaccination was reported as not applicable. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient reported that, on 28Mar2021 at 12:00, two days (2 days 2 hrs 45 min) after first dose, she started having elevated heart rate, shortness of breath, chest tightness, dizziness and interrupted sleep due to these symptoms. She was still experiencing this (day 12 after vaccine). The events were reported as non-serious. The adverse events resulted in Doctor or other healthcare professional office/clinic visit and Emergency room/department or urgent care. She went to the ER (emergency room) on 31Mar2021 and followed up with cardiologist on 06Apr2021. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient had been tested for COVID-19 via Nasal swab sample on 03Apr2021 and the results came out to be negative. It was unknown if corrective treatment received for the adverse event. The outcome for the events was reported as not recovered at the time of report. No follow-up attempts are needed. No further information is expected.
1000 vaccine recieved and pain started after he felt a pop, (instructed him this was the vanish shield needle most likely)  followed by numbness and tingling. When he walked to chair become dizzy and light headed. 1005 reported issues to recovery staff. b/p 132/78, p-99, 02 sat 97%ra, r-18. 1019 cont to be dizzy and light headed, tingling wrist down, pain is gone @ this time. 1023 starting to get sleepy per report. 1045 c/o of vision alterations, blurry vision. B/P 152/80, p-99,02 sat 96%ra, r-18. 1100 b/p 140/86, p-99, r-18, 02 sat 97%. Reports cont to feel the same. 1105 Site lead instructed pt to call MD, go to urgent care or we could call EMS. Pt and significant other opted to drive via their car to urgent care.
This case was reported by a healthcare professional and described the occurrence of a 56-year-old male subject not responding to therapy following vaccination with Engerix B for prophylaxis. On 11 July 2007, 19 February 2007 and 11 January 2007 the subject received 3rd dose, 2nd dose and 1st dose of Engerix B (unknown). On 11 September 2007, it was noted that the subject had not seroconverted or did not respond to therapy with Engerix B. At the time of reporting the event was unresolved.
This spontaneous report as received from a medical assistant refers to a 4 month old patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 31-OCT-2018, the patient was vaccinated with improperly stored dose of ROTATEQ 2 ml tube, orally (lot # R007988, expiry date: 16-OCT-2019) for prophylaxis. The vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) and time frame was 3.5 hours from 06-SEP-2018. Previous excursion was 50.37 °F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source.; Sender's Comments: US-009507513-1809USA002868: Original Case : 1809USA002868 US-009507513-1902USA009324: Original Case : 1902USA009323 US-009507513-1902USA009325: Original Case : 1902USA009323 US-009507513-1902USA009323: Original Case : 1902USA009323.
This non-serious initial spontaneous case was received from other non-health professional on 13-Nov-2017, concerning a 42-year-old, adult, female patient. On an unspecified date in Oct-2017, the patient was administered with FLUCELVAX QIV (dose, route of administration, anatomical location, batch number and expiry date: not reported). On 15-Oct-2017, the patient experienced pain in whole arms down to her wrists. It was reported that, the pain lasted for 20 minutes. On the following day, her arms were little bit itchy. The outcome of the event pain was recovered and 'little bit itchy' was not reported.
Redness/swelling at site of injection within 4-5 hours after injection. Instructed by MD to apply ice pack, take tylenol if needed.
Myalgia, Arthralgia & Fever Narrative:  dose 1-day1-3 pain on shoulder dose 2- day 1-3 pain on shoulder/rash; 2-3 - fever; chills; fatigue; muscle pain
headache; soreness at the injection site on the second day; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 72 year-old female patient received bnt162b2 (BNT162B2), administration date 02Mar2021 (Lot number: EN5318, Expiration Date: 31May2021) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose, Verbatim: the first vaccine was on 09Feb2021, expiration date 30Apr2021, EL1284, she had no problems with it, not even soreness.), administration date: 09Feb2021, for Covid-19 immunisation. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 03Mar2021, outcome "unknown", described as "soreness at the injection site on the second day"; HEADACHE (non-serious), outcome "unknown", described as "headache". Therapeutic measures were taken as a result of vaccination site pain.  Additional information: The patient reported that she had chicken soup and was better after, she rubbed the injection site with alcohol, she had no fatigue.  No follow-up attempts are possible. No further information is expected.
"Received vaccine around 12:30pm. Around 8pm lips/tongue started tingling and swelling. Tongue broke out in sores. Took 4-5 doses of Benadryl  from 8pm on 1/19/21 to 1pm on 1/20/21, swelling resolved, some sores still present." The employee was placed "off work" from 1/20/21-1/23/21 and was prescribed one tablet daily of Zyrtec or Allegra over the counter.
10 days after the vaccine I had gotten up and looked in the mirror and my arm was swollen and tender. I called my Doctor and I called the physician on call and they said to do a warm compress which I did and it helped, and she prescribed me some steroids which I didn't need but between the steroids and warm compresses, within 36 hours it subsided. There was swelling and redness around the injection site.
Woke up the day after vaccine feeling fine so I got ready & headed for work.  On the way to work I started feeling a little off & nauseous. Ended up leaving work a little over 2 hours after I started.  I was feeling nausea, achy, chills, fatigue, dizziness/lightheaded, sore arm.  Went home and to bed.  Still fatigued, sore arm and a little achy the next day.  Now on day 4 since vaccine and am still experiencing a sore arm & fatigue(improving but not back to my normal energy level).  On a positive note my ongoing sinus symptoms(since June 2020) have improved.  They are not gone but noticeably improved.  I'm thankful for that and hoping it lasts!!!!
polyarticular inflammation (erythema, tenderness) in 2 finger joints and probably L wrist as well, consistent with a type 3 hypersensitivity reaction (immune complex deposition) DESPITE the fact that i was already taking prednisone daily because i anticipated severe side effects because i had a covid and has significant side effects from the first vaccine. i have continued to take prednisone and the symptoms are improving.  i believe that people who have already had covid should not receive 2 doses of the vaccine as the first dose is in essence a booster. allot of people who have had covid are reporting significant side effects with the vaccine, especially the second dose. this needs to be addressed.
Client states that upon waking on 2/12/2018 left eye swollen and she is unable to use left hand. Referred to PMD and will follow-up with client on 02/14/2018.
According to the MD, the pt complained of fatigue, chills, some liver tenderness and was going to be check for mononucleosis, liver enzymes. Symptoms started 1 day post vax. The pt's mother states that she had a reaction to the first injection but did not report it.
By end of 4/20/04 developed mild erythema. Next day left deltoid was indurated firm, warm, red. Seen 4/22/04. Given PRN Prednisolon 7.5ml po. Po x 5 days. benadryl po. Seen 4/21/04-90% recovered.